12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Forxiga dapagliflozin: Phase III data

A double-blind, international Phase III trial in 447 Type II diabetics aged 18 and older who were inadequately controlled with sitagliptin with or without metformin showed that once-daily 10 mg dapagliflozin in combination with sitagliptin with or without metformin met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo plus sitagliptin with or without metformin (placebo-adjusted reduction of 0.48%, p<0.0001). On secondary endpoints, dapagliflozin plus sitagliptin with or without metformin led to significant placebo-adjusted reductions from baseline to week 24 in mean FPG (23.3 mg/dL, p<0.0001) and body weight (1.89 kg, p<0.0001). Dapagliflozin did not significantly reduce SBP from baseline to week 24...

Read the full 514 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >